AEI.Org: Scholar: John E. Calfee

Limiting Drug Prices Means Limiting Future Cures

Sat, 10 Oct 2009 00:00:00 +0100

Controls would take away the industry's incentive to develop new lifesaving medications and therapies.

What Do Vitamins and Fish Oil Tell Us about Drug Research?

Thu, 06 Aug 2009 00:00:00 +0100

There is a second world of drug research, a world in which patents do not exist and for-profit research is permanently moribund. Its history should stop "reformers" in their tracks.

The Dangers of Fannie Mae Health Care

Fri, 26 Jun 2009 00:00:00 +0100

A public health care plan would have certain advantages. That's precisely the problem.

A Public Health Disaster in the Making

Wed, 03 Jun 2009 00:00:00 +0100

Congress is poised to pass one of the worst public health laws ever conceived.

Decoding the Use of Gene Patents

Fri, 15 May 2009 00:00:00 +0100

The U.S. Patent and Trademark Office has resisted researchers' overreaching in their patenting of genes, and researchers' work is seldom compromised by patents.

Learning a Little about Drug Companies from The Lancet

Thu, 26 Mar 2009 00:00:00 +0100

Democrats have made clear that the lifesaving drug industry will soon face politically inspired assaults.

A Troubling Supreme Judgment

Fri, 06 Mar 2009 00:00:00 +0100

The Supreme Court's decision in Wyeth v. Levine will be negative for patient welfare.

Medicine's Miracle Man

Fri, 23 Jan 2009 00:00:00 +0100

Maurice Hilleman's remarkable period of industrial scientific research yielded the most cost-effective medicines ever made.

Tough Challenges at the FDA

Thu, 15 Jan 2009 00:00:00 +0100

Obama's FDA commissioner should avoid actions that make the drug development process more costly and inefficient.

Seeding Sales and Science

Mon, 25 Aug 2008 00:00:00 +0100

Marketing-driven clinical pharmaceutical trial intend to increase sales and profits but also yield enormous benefits for patients.

The Indispensable Industry

Wed, 11 Jun 2008 00:00:00 +0100

New efforts to undermine the country's drug development system are cause for worry.

Drugs Kennedy Needs

Wed, 04 Jun 2008 00:00:00 +0100

The FDA's restrictive approach toward new drugs, supported by Senator Ted Kennedy,comes at the expense of many patients and possiblyKennedy, too.

Patents Pending

Fri, 01 Feb 2008 00:00:00 +0100

The U.S. patent system is more important than ever. It is also a mess, but help may finally be on the way.

Can Quality-Adjusted Life Year Avoidance Help in Oncology Drug Reimbursement Decisions?

Tue, 01 Jan 2008 00:00:00 +0100

It is better to require oncologist members of reimbursement committees to ponder trade-offs than to allow those trade-offs to languish in obscurity.

Congress's Patent Mistakes

Mon, 29 Oct 2007 01:00:00 +0100

Government should address intellectual property reform carefully and with caution.

Congress's Patent Mistakes

Mon, 29 Oct 2007 01:00:00 +0100

Government should address intellectual property reform carefully and with caution.

An Assessment of Direct-to-Consumer Advertising of Prescription Drugs

Mon, 01 Oct 2007 00:00:00 +0100

Doesprescription drug advertisinginduce excess or danger inprescribing practices?

Patent Challenges Have Wide Impact on Big Pharma

Fri, 31 Aug 2007 00:00:00 +0100

In patent politics there is more at stake than money.

SCHIP Guidelines: Principles for Health Insurance Coverage for Children and Families

Mon, 21 May 2007 00:00:00 +0100

Scholars offer considerations for the reauthorization of the State Children's Health Insurance Program.

Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation

Tue, 01 May 2007 00:00:00 +0100

Strong property rightsand minimal interference will ensuretheefficiency and success of the pharmaceutical industry.

FDA Steps Backward

Tue, 24 Apr 2007 00:00:00 +0100

The FDA's recent move was a giant step toward a calamitous new drug approval policy.

The Golden Age of Medical Innovation

Fri, 06 Apr 2007 00:00:00 +0100

Innovation in drugs and medical devices in the U.S. is rampant.

Lessons of the Heart

Tue, 03 Apr 2007 00:00:00 +0100

A surprising new study on heart disease treatments will not just change medicine--it will help shape basic science.

Pushing Too Far

Wed, 28 Mar 2007 01:00:00 +0100

Congress has pushed the FDA too far with its new rules.

The Truth about the Drug Ads

Fri, 02 Feb 2007 00:00:00 +0100

Many people love to hate direct-to-consumer advertising, but research suggests the ads do more good than harm.

Regulating Access to Developmental Drugs for Terminally Ill Patients

Thu, 18 Jan 2007 00:00:00 +0100

An amicus brief regarding Abigail Alliance v. FDA.

The Real Dangers of Medicare

Fri, 12 Jan 2007 00:00:00 +0100

At a time when cancer, Alzheimer's, and other vicious diseases would benefit most from technological advances, a new law may attempt to stifle innovation.

FDA Advisory Committees and Conflicts of Interest

Wed, 11 Oct 2006 00:00:00 +0100

Attempts to abolish conflicts of interest in the FDAcould tie the organization'shands as it goes about the crucial task of marshalling the best scientific advice.

Drug Dilemma

Sun, 08 Oct 2006 00:00:00 +0100

Derived partly from his own research and analysis,Richard Epstein summarizes an immense literature while digging into knotty issues in the pharmaceutical industry.

The Emerging Market Dynamics of Targeted Therapeutics

Tue, 12 Sep 2006 00:00:00 +0100

Targeted biotech drugs that attack specific biological molecules that cause disease are bringing new benefitsand fomentingpricing dynamics different from those of traditional drugs.

Patient Power

Mon, 08 May 2006 00:00:00 +0100

The FDA needs to know what patients want, and it should give those preferences very great weight.

Who's Aided by Impasse over Vote for FDA Chief?

Wed, 19 Apr 2006 00:00:00 +0100

It's time for Plan C. Clinton and her allies should let the Senate vote on the von Eschenbach nomination.

Rein in the Monster

Wed, 12 Apr 2006 00:00:00 +0100

ANew Jersey jury awarded compensationto John McDarby, 77,who sued Merck after suffering a heart attack while taking the pain reliever Vioxx.

For the Birds or Sleeping with the Fishes?

Tue, 14 Mar 2006 00:00:00 +0100

What are the odds of another pandemic--this time, bird flu--happening?

Striking a Balance

Mon, 30 Jan 2006 00:00:00 +0100

How will new prescription label requirements affect pharmaceutical companies?

Creating a Thriving Biodefense Marketplace

Mon, 23 Jan 2006 00:00:00 +0100

While the world stands transfixed by the specter of a pandemic flu, a very different threat, bioterrorism, remains largely unaddressed.

The Truth about Drug Companies and "On the Take"

Wed, 26 Oct 2005 00:00:00 +0100

Two recent books, Marcia Angell's The Truth About Drug Companies and Jerome Kassirer's On the Take are often grouped with other anti-pharmaceutical-industry tracts.

First, Do No Harm

Tue, 18 Oct 2005 00:00:00 +0100

The best way to confront a brand new flu bug is to avoid being swept by hysteria into serious policy mistakes.

What the Texas Jury Did to Patients

Thu, 08 Sep 2005 00:00:00 +0100

Verdicts like the one against Vioxx could end up denying valuable new drugs to patients.

Junk Science Reigns

Mon, 22 Aug 2005 00:00:00 +0100

The American tort liability systemworks badly when it gets infected by junk science.

To Really Stop Smoking

Wed, 06 Jul 2005 00:00:00 +0100

If the anti-tobacco community really thinks higher prices are good for smokers, it shouldwork on passinga tax law instead of squiggling past Congress by bringing lawsuits.

Where There's Smoke

Mon, 18 Apr 2005 00:00:00 +0100

Want to get people to quit smoking? Give them more ways to get nicotine.

A Joint Statement on Drug Importation

Thu, 14 Apr 2005 00:00:00 +0100

Two scholars speak out on drug importation.

Is the FDA Broken?

Wed, 30 Mar 2005 00:00:00 +0100

Congress should just let the Food and Drug Administration get on with its job.

Does Pharma Need a New Prescription?

Mon, 31 Jan 2005 00:00:00 +0100

John Calfee reviews Marcia Angell's book The Truth about the Drug Companies: How They Deceive Us and What to Do about It.

Pharmaceuticals and the Worldwide HIV Epidemic

Fri, 01 Oct 2004 00:00:00 +0100

Adoption of a stakeholder approach is likely to undermine essentialresearch and developmentwhile doing little to curtail the HIV/AIDS epidemic.

The Cost of Medicine

Thu, 26 Aug 2004 00:00:00 +0100

John E. Calfee and Merrill Goozner debate the question of how much the government can and should do about the cost of medicines, now and in the future.

Paying for the Pills

Tue, 01 Jun 2004 00:00:00 +0100

Review of The $800 Million Pill: The Truth behind the Cost of New Drugs by Merrill Goozner.

The High Price of Cheap Drugs

Mon, 21 Jul 2003 00:00:00 +0100

The House is tempted by a terrible idea.

What Do We Know about Direct-to-Consumer Advertising of Prescription Drugs?

Wed, 26 Feb 2003 00:00:00 +0100

The emerging evidence on DTC advertising is consistent with a larger pattern in which marketing has been found to increase consumer welfare.

Patently Wrong

Tue, 28 Jan 2003 00:00:00 +0100

A fusillade of criticism has fallen upon the United States for being the lone holdout in a WTO proposal to encourage poor nations to import generic versions of patented drugs.

Why Drugs from Canada Won't Cut Prices

Fri, 01 Nov 2002 00:00:00 +0100

Consumers should understand how reimportation would work if it were actually put in place, because it would be a classic example of unintended consequences.

Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs

Mon, 23 Sep 2002 00:00:00 +0100

Little is known about the effects of DTC advertising, especially its impact on consumer behavior (as opposed to attitudes and knowledge) and, ultimately, on consumer health.

Legislation to Allow Reimporting Drugs from Canada Would Raise Prices There Rather Than ...

Sun, 22 Sep 2002 00:00:00 +0100

Drugs are cheaper in Canada than in the United States, leading the Senate to back a bill that would allow the reimportation of U.S.-made drugs from Canada.

Drug Re-importation from Canada

Thu, 01 Aug 2002 00:00:00 +0100

Drug Ads Should Be Left Alone

Sun, 17 Mar 2002 00:00:00 +0100

Studies show that drug advertising actually saves consumers money by alerting them to the benefits of new medicines that prolong and enhance life and reduce hospital stays.

Pharmaceutical Patents and Public Safety

Thu, 01 Nov 2001 00:00:00 +0100

Recent events have changed bioterrorism from a theoretical threat into an immediate one; weneed tools for dealing with bioterrorism when it occurs.

Pharmaceutical Price Controls and Patient Welfare

Tue, 05 Jun 2001 00:00:00 +0100

Pharmaceutical price controls offer short-term gains for a small proportion of patients at the cost of curtailing research that promises to bring far better therapies in the future.

The Unintended Consequences of Price Controls

Tue, 02 Jan 2001 00:00:00 +0100

Price controls persist because health agencies can benefit from a system that reliably protects profits and discourages new entrants while assuring stability in prices and expenditures.

The Historical Significance of Joe Camel

Sun, 01 Oct 2000 00:00:00 +0100

When R. J. Reynolds brought its Joe Camel cartoon character from France in 1988 for use in the United States, it launched a controversy that outlived the character itself.

Be Wary of Drug-Price Controls

Thu, 06 Jul 2000 00:00:00 +0100

Rather than latching onto the folly of other nations, we should be urging Canada and European nations to dismantle their own drug-price controls.

Bills to Equalize Rx Drug Prices in Unites States and Canada Show Crackpot Economics Is ...

Tue, 04 Jul 2000 00:00:00 +0100

Rather than latching onto the folly of other nations, we should be urging Canada and European nations to dismantle their own drug-price controls.

Drugs, Drug Prices, and Your Health

Mon, 01 May 2000 00:00:00 +0100

Pharmaceutical costs have aroused controversy for decades, but debate has intensified over the past year.

Price Controls Are a Prescription for Disaster

Thu, 22 Jul 1999 00:00:00 +0100

It would be too easy, in an effort to cut costs, to constrict the pipeline that is producing one new wonder drug after another.

Healing a National Case of Asbestosis

Wed, 12 Aug 1998 00:00:00 +0100

The time has come for Congress to act on the asbestos litigation.

A Legal Nightmare for Asbestos' Real Victims

Sun, 02 Aug 1998 00:00:00 +0100

While tobacco liability continues to occupy Congress, another liability issue has bedeviled the courts and tortured victims for many years.

Why the War on Tobacco Will Fail

Mon, 20 Jul 1998 00:00:00 +0100

The Litigation Logjam We Can Clear

Mon, 20 Jul 1998 00:00:00 +0100

It is time for Congress to act on the litigation problems caused by asbestos cases.

How Advertising Informs to Our Benefit

Wed, 01 Apr 1998 00:00:00 +0100

A great truth about advertising is that it is a tool for communicating information and shaping markets.

The Ghost of Cigarette Advertising Past

Sun, 01 Jun 1997 00:00:00 +0100

In light of the current debate over the regulation of cigarettes, this piece concerning the consequences of limiting tobacco advertising is particularly relevant.

Efficiency Begets Fairness

Mon, 10 Feb 1997 00:00:00 +0100

Class action settlements avoid the mammoth costs and delay of individual lawsuits or traditional class action litigation.

Solving the Asbestos Litigation Morass

Tue, 26 Nov 1996 00:00:00 +0100

One must face the fact that litigation is no substitute for mass settlements, nor is it a rational and humane method for compensation.

Discussion on the Economics of the Georgine Settlement

Wed, 16 Oct 1996 00:00:00 +0100

If the Supreme Court decides to take the Georginecase, it can allow the legal system to retrieve a semblance of justice from what a deplorable exercise in using injured plaintiffs.

FDA

Tue, 01 Oct 1996 00:00:00 +0100

The Industry Effects of Information and Regulation in the Cigarette Market

Tue, 01 Oct 1996 00:00:00 +0100

It is important tomake an independent assessment of the likely effects of proposed advertising bans and other interventions in informational competition.

Smoking Alternatives

Mon, 16 Sep 1996 00:00:00 +0100

Uncle Sam, M.D.

Wed, 15 Apr 2009 00:00:00 +0100

This collection of essays provides an indication of the range and depth of AEI’s work in health care reform and pharmaceutical policy.

Biotechnology and the Patent System

Tue, 25 Sep 2007 00:00:00 +0100

This book offers a timely discussion of biotechnology patent reform.

Prices, Markets, and the Pharmaceutical Revolution

Tue, 01 Feb 2000 00:00:00 +0100

This book explains why efforts to control drug prices through political means are deeply misconceived and could thwart today's dramatic improvements in health.

Fear of Persuasion

Mon, 01 Sep 1997 00:00:00 +0100

This book addresses the most prominent policy issues raised by advertising--competition, consumer information, children, ad bans, and free speech.

September 15 Health Care Conference Call

Tue, 15 Sep 2009 13:30:00 +0100

Conference Call: Health Care Reform

Wed, 22 Jul 2009 10:30:00 +0100

The Five (Not So) Easy Pieces of Health Reform

Thu, 04 Jun 2009 09:00:00 +0100

U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies

Fri, 08 May 2009 10:00:00 +0100

Pharmaceutical Price Regulation: Public Perceptions, Economic Realities, and Empirical ...

Tue, 17 Feb 2009 09:00:00 +0100

Implications of Medicare Part D

Tue, 14 Oct 2008 10:00:00 +0100

Autism's False Prophets

Fri, 10 Oct 2008 14:30:00 +0100

Innovation and Technology Adoption in Health Care Markets

Mon, 22 Sep 2008 16:00:00 +0100

Off-Label Uses of Approved Drugs: Medicine, Law, and Policy

Wed, 21 May 2008 09:45:00 +0100

Oncology Drug Development: Rethinking FDA Oversight

Thu, 13 Mar 2008 10:30:00 +0100

The Vioxx Settlement

Mon, 07 Jan 2008 13:00:00 +0100

Vaccinated: The Quest for New Vaccines Yesterday and Today

Tue, 09 Oct 2007 11:00:00 +0100

Biotechnology and the Patent System: The Economic Implications of the Proposed Patent ...

Tue, 25 Sep 2007 09:30:00 +0100

What Should Congress Do about Generic or Follow-On Biologic Drugs?

Mon, 11 Jun 2007 13:00:00 +0100

Can Government Price Negotiation Work for the Medicare Drug Benefit?

Fri, 19 Jan 2007 15:00:00 +0100

Does the United States Need a NICE?

Wed, 28 Jun 2006 10:30:00 +0100

The Cutter Incident

Fri, 14 Apr 2006 10:00:00 +0100

Medical Malpractice Liability and Physician Supply

Wed, 05 Apr 2006 10:00:00 +0100

Getting the Most Innovative Drugs to Market: What Can the FDA Do?

Tue, 07 Feb 2006 14:00:00 +0100

Knowledge and the Growth Process

Thu, 02 Feb 2006 15:00:00 +0100

Conflict of Interest or Fruitful Collaboration?

Fri, 16 Sep 2005 09:30:00 +0100

The $253 Million Vioxx Verdict

Wed, 07 Sep 2005 10:00:00 +0100

Tort Reform

Thu, 21 Apr 2005 15:00:00 +0100

The Perils of Re-importation

Fri, 15 Apr 2005 13:00:00 +0100

Is There a Crisis in Medical Malpractice?

Thu, 31 Mar 2005 09:15:00 +0100

Follow-on Drug Development

Wed, 15 Dec 2004 09:15:00 +0100

Improving Health Care

Mon, 08 Nov 2004 11:00:00 +0100

What Happened to the European Pharmaceutical Industry?

Thu, 07 Oct 2004 15:00:00 +0100

Show Us the Data

Mon, 20 Sep 2004 09:30:00 +0100

Assuring Vaccine Supply

Thu, 15 Apr 2004 11:00:00 +0100

The Price of Pharmaceuticals

Fri, 12 Dec 2003 10:15:00 +0100

Medicare after Reform

Thu, 04 Dec 2003 09:00:00 +0100

Tackling Malaria

Tue, 02 Dec 2003 14:00:00 +0100

A New Approach to Vaccine Development

Mon, 01 Dec 2003 11:00:00 +0100

Unrestricted Prescription-Drug Importation from Canada and Elsewhere

Thu, 02 Oct 2003 10:00:00 +0100

Pharmaceutical Products, TRIPS, and the Doha Round

Tue, 02 Sep 2003 15:00:00 +0100

Can Smokeless Tobacco Reduce the Health Consequences of Smoking?

Wed, 25 Jun 2003 13:30:00 +0100

Obesity, Individual Responsibility, and Public Policy

Tue, 10 Jun 2003 12:00:00 +0100

Direct-to-Consumer Advertising of Prescription Drugs

Tue, 27 May 2003 14:30:00 +0100

The Worldwide Campaign against Pharmaceutical Innovation

Tue, 18 Mar 2003 11:00:00 +0100

Politics, Policy, and Progress in Health Care

Wed, 11 Dec 2002 12:00:00 +0100

International Pharmaceutical Markets

Mon, 18 Nov 2002 10:00:00 +0100

Vaccine Development and Biodefense

Tue, 25 Jun 2002 09:30:00 +0100

The New Pharmaceutical Litigation

Tue, 18 Jun 2002 10:00:00 +0100

Is More Health Information Better?

Fri, 14 Jun 2002 09:15:00 +0100

Gene-Related Inventions

Thu, 18 Apr 2002 10:30:00 +0100

The OxyContin "Crisis"

Thu, 07 Feb 2002 10:30:00 +0100

Is the Pharmaceutical Revolution Paying Off?

Tue, 29 Jan 2002 11:00:00 +0100

Bioterrorism and Pharmaceuticals

Thu, 01 Nov 2001 10:00:00 +0100

The Future of Human Health

Mon, 18 Jun 2001 17:30:00 +0100

Pharmaceutical Pricing Proposals

Mon, 24 Jul 2000 09:30:00 +0100

The Tail of the Weight Distribution

Fri, 09 Jun 2000 09:15:00 +0100

Prices, Markets and the Pharmaceutical Revolution

Fri, 28 Jan 2000 16:00:00 +0100

A Briefing on the State of the Union

Thu, 27 Jan 2000 08:30:00 +0100

The Safety of Pharmaceuticals

Fri, 26 Mar 1999 00:00:00 +0100

What Can the European Union Do to Sharpen Its Innovative Edge in Pharmaceuticals?

Tue, 14 Apr 2009 00:00:00 +0100

There are good reasons for the European Union to worry about the health of its pharmaceutical firms, but fortunately there are things it can improve.

Supreme Court Amicus Brief Regarding Wyeth v. Diana Levine

Tue, 03 Jun 2008 00:00:00 +0100

The U.S. Supreme Court recieved an amicus brief on FDA regulation.

FDA Preemption of State Tort Liability Lawsuits on FDA-Regulations Drugs and Devices

Wed, 14 May 2008 00:00:00 +0100

The commonly held view that state tort liability litigation can do much good and little harm because it provides added protection to patients and consumers is largely unsupported.

FDA Oversight of Drug Safety

Wed, 27 Feb 2008 01:00:00 +0100

Testimony in defense of the FDA, which has come under attack recently for its handling of drug safety.

Medicaid Prescription Drugs

Wed, 22 Jun 2005 00:00:00 +0100

Government reimbursement programs often create cross-subsidies and other distortions that greatly complicate the task of setting reasonable and efficient reimbursement levels.

The Roles of FDA and Pharmaceutical Companies in Ensuring the Safety of Approved Drugs, ...

Thu, 05 May 2005 00:00:00 +0100

Post-approval drug safety surveillance is an extraordinarily difficult task.The Vioxx episode has probably made it more difficult for the Food and Drug Administration to do its job.

Why We Should Preserve the American System for Pharmaceutical Research and Development

Mon, 17 Jan 2005 00:00:00 +0100

We have a pharmaceutical research and development system that really works.

International Pharmaceutical Pricing

Tue, 27 Apr 2004 00:00:00 +0100

Price controls that keep the price of pharmaceuticals below market levels impede access to drugs, discourage drug development, and allow other countries to free-ride on American R&D.

A Critical Look at the New Litigation against Alcoholic Beverage Advertising

Wed, 24 Mar 2004 00:00:00 +0100

The current wave of alcoholic beverage litigation is part of a larger trend toward regulation by litigation and will probably fail.

Pharmaceutical Price Controls

Wed, 11 Feb 2004 00:00:00 +0100

Testimony before the House Committee on Industrial Relations for the State of Georgia on the harmful effects of a bill to enact comprehensive pharmaceutical price controls.

First Amendment Issues

Fri, 13 Sep 2002 00:00:00 +0100

Testimony before the Food and Drug Administration on September 13, 2002, on how the FDA can assure that its controls over commercial speech conforms to Supreme Court decisions.

National Immunization Program

Tue, 27 Nov 2001 00:00:00 +0100

What are the economic barriers to bioterrirism vaccine development and distribution and the problem of liability exposure?

What Role Will Germany Have In the Revolution in Medicine?

Thu, 11 Oct 2001 00:00:00 +0100

Germany will be an observer and a consumer of the fruits of the pharmaceutical revolution, but it will not be one of its leaders.

Direct-to-Consumer Advertising of Prescription Drugs

Thu, 19 Jul 2001 00:00:00 +0100

Direct-to-consumeradvertising appears to make patients more comfortable with the risks and benefits of the medicines they take.

Comments to the World Health Organization

Tue, 30 May 2000 00:00:00 +0100

The WHO can usefully focus on two things: supporting a shift in attitudes and leadership, especially in the health care community; and permitting the marketplace to make tobacco use safer.

Hearing on Seniors' Access to Prescription-Drug Benefits

Tue, 15 Feb 2000 00:00:00 +0100

White Hous plans offer hope for a Medicare drug benefit that would permit the pharmaceutical research revolution to continueand introducingmore life-saving and life-improving therapies.

An Exploratory Analysis of Pharmaceutical Price Disparities and Their Implications among ...

Thu, 13 Apr 2006 00:00:00 +0100

This piece reviews earlier work on international pharmaceutical prices and then brings to bear a data set that permits us to explore questions not previously addressed.

A Representative Survey of M.S. Patients' Attitudes toward the Benefits and Risks of Drug ...

Tue, 28 Mar 2006 00:00:00 +0100

A study regarding Multiple Sclerosis patients' attitudes about the risks and benefits of drug therapy.

Innovative Drug Development in the Context of FDA Regulation

Wed, 01 Feb 2006 00:00:00 +0100

How severe is the crisis in the pharmaceutical industry?

An Exploratory Analysis of the Determinants of Pharmaceutical Price Disparities among Six ...

Wed, 01 Jun 2005 00:00:00 +0100

This is a study of international disparities in prescription drug prices between the United States and five OECD nations (Australia, Canada, France, Germany, and the U.K.).

The Significance of the Vioxx Withdrawal

Wed, 06 Apr 2005 00:00:00 +0100

An examination of Cox-2 class drugs for assessing Merck's decision to withdraw Vioxx.

Direct-to-Consumer Advertising of Prescription Medicines in the United States and New Zealand

Thu, 27 May 2004 00:00:00 +0100

The authors examine direct-to-consumer advertising in the United States and New Zealand,the New Zealand self-regulatory model, and consumer survey results from both countries.

Bioterrorism and Pharmaceuticals

Wed, 31 Oct 2001 23:00:00 +0100

We need tools for dealing with bioterrorism when it occurs, and among these tools are pharmaceuticals.

A Representative National Survey of Oncologists FDA on Off-Label Prescribing and Policies ...

Fri, 12 Sep 1997 00:00:00 +0100

On July 21, 1997,AEI and the American Cancer Societyreleased the results of a telephone survey of a representative sample of 200 practicing oncologists such as cancer specialists.

And Now, a Few Words about Antivirals for Pandemic Flu

Tue, 02 Jun 2009 00:00:00 +0100

The development of antivirals for pandemic flu provides important insights into the pharmaceutical industry's ability to advance public health.

When Patents Are Not Enough

Mon, 08 Dec 2008 00:00:00 +0100

Congress should act in protecting patents for follow-on biologics, relying on a few basic principles that do not suppress research and developmentin this vital sector.

FDA Preemption and Patient Welfare in Wyeth v. Levine

Mon, 03 Nov 2008 00:00:00 +0100

The Supreme Court's decision in Wyeth v. Levine could lead the FDA to require excessive warnings on medications and impose "contraindications" that would constrain medical practice.

Reform without Reason

Wed, 26 Sep 2007 00:00:00 +0100

The FDAAmendments Act of 2007 will bring the most important changes in FDA regulation in at least a decade, but it is an unnecessary law.

Facing Reality on Follow-On Biologics

Tue, 24 Apr 2007 00:00:00 +0100

Follow-on biologics are not like ordinary generics, and therefore require Congress to exercise a deft regulatory hand.

Playing Catch-up

Tue, 28 Mar 2006 00:00:00 +0100

With the fates of the Food and Drug Administration and the pharmaceutical industry more intertwined than ever, our health depends on regulatory innovation as much as on scientific progress.

The Vioxx Fallout

Fri, 30 Sep 2005 00:00:00 +0100

New research findings and a thorough reassessment of older research indicate that drugs like Vioxx can have many important benefits and great potential for addressing serious problems.

Putting Markets to Work in Vaccine Manufacturing

Mon, 01 Nov 2004 00:00:00 +0100

Legislators should adopt policies that encourage companies to make vaccines more quickly and less expensively.

Of Sausage-Making and Medicare

Thu, 01 Jan 2004 00:00:00 +0100

Through the Medicare Act of 2003, private plans will offer more services to seniors, but with restrictions that could blunt the effectiveness of competition in restraining cost growth.

The Grim Economics of Pharmaceutical Importation

Sat, 01 Nov 2003 00:00:00 +0100

Pressureis buildingto give Americans access to prescription drugs from price-controlled nations, yet legislation needs to consider the effects of allowing unrestricted importation.

The Supreme Court's Wyeth Blunder

Mon, 16 Mar 2009 00:00:00 +0100

The Supreme Court's Wyeth decision will hurt new drug development and limit physicians' willingness to use certain drugs.

Tough Challenges at the FDA

Wed, 21 Jan 2009 00:00:00 +0100

President Obama's FDA commissioner should avoid actions that make the drug development process more costly and inefficient.

Seeding Sales and Science

Tue, 23 Sep 2008 00:00:00 +0100

Regardless of the intentions, clinical drug trials driven primarily by marketing yield enormous benefits for patients and practitioners.

Drugs Kennedy Needs

Tue, 10 Jun 2008 00:00:00 +0100

The FDA's restrictive approach toward new drugs, supported by Senator Ted Kennedy, comes at the expense of many patients and possibly Kennedy, too.

The Truth about the Drug Ads

Fri, 16 Mar 2007 01:00:00 +0100

Looming on the horizon is a political battle over direct-to-consumer advertising of prescription drugs.

Striking a Balance

Fri, 10 Feb 2006 00:00:00 +0100

A new Food and Drug Administration labeling rule could provide better information to consumers and prevent hyperactive litigation.

Junk Science Reigns

Thu, 01 Sep 2005 00:00:00 +0100

The recent verdict in a case involving the pain reliever Vioxx demonstrates how junk science can corrupt drug litigation.

The High Price of Cheap Drugs

Tue, 01 Jul 2003 00:00:00 +0100

Reimportating drugs would mean importing foreign price controls, which would have disastrous consequences for future drug research and development.

Pharmaceutical Price Controls Are a Prescription for Disaster

Thu, 22 Jul 1999 00:00:00 +0100

Bill Clinton's proposed drug benefit for Medicare recipients is predicated on driving down the cost of drugs that elderly Americans need.

Why Pharmaceutical Price Controls Are Bad for Patients

Mon, 08 Feb 1999 00:00:00 +0100

Fixing drug prices at lower levels would inevitably curtail development and distribution of new products that improve and extend life.

Why the War on Tobacco Will Fail

Mon, 20 Jul 1998 00:00:00 +0100

The campaign to reduce smoking by attacking the tobacco industry rather than the habits of individual smokers will not succeed.